0
0.5
1
1.5
2+
Symp. case
93%
Improvement
Relative Risk
Case
93%
Casirivimab/i.. Isa et al. Prophylaxis DB RCT
Is prophylaxis with casirivimab/imdevimab beneficial for COVID-19?
Double-blind RCT 969 patients in the USA (July 2020 - May 2021)
Fewer symptomatic cases (p=0.0019) and cases (p=0.0018)
c19early.org
Isa et al., medRxiv, November 2021
Favors casirivimab/im..
Favors control